Shi Yi is a prescription medication primarily intended for the symptomatic management of chronic inflammatory conditions. It may help reduce the severity of pain and swelling associated with persistent musculoskeletal discomfort.

The medication may be used for a range of conditions, including the management of certain types of arthritis, relief of persistent joint pain, and lessening the impact of inflammatory flares. As part of a comprehensive care plan, Shi Yi may help improve overall functional capacity in patients managing specific autoimmune diseases, supporting the ability to maintain daily activities.

---

Quick Fact: Relief for Persistent Discomfort

The eligibility for Shi Yi, which contains Finasteride, is strictly defined by authoritative regulatory documents and is limited to adult men.

Contraindications and Non-Eligibility

Population Group	Regulatory Status
Women	Contraindicated and Not Indicated for Use
Pregnancy	Contraindicated (Due to risk to male fetus)
Pediatric Patients (<18)	Not Indicated for Use (Safety/efficacy not established)
Hypersensitivity	Contraindicated to finasteride or excipients

Official labeling mandates that women who are pregnant or may become pregnant must not handle crushed or broken tablets, as the active ingredient can be absorbed through the skin. The drug is explicitly not indicated for use in women or children.

Conditional and Established Use

Condition / Age Group	Regulatory Guidance
Renal Impairment	No dosage adjustment is necessary
Hepatic Impairment	Caution should be used (Metabolized extensively in the liver)
Older Adult Men (Geriatric)	No dosage adjustment is necessary

Eligibility is defined by specific criteria: the drug is permitted for use in adult men, including older adults and those with renal impairment. However, caution is advised for patients with liver function abnormalities, as the effect of impairment on the drug's metabolism has not been fully studied in this population.

Interactions with other medicines and products

The official regulatory profile for Shi Yi (Finasteride) is defined by a low potential for clinically significant drug interactions. This low risk is based on the finding that the medicine does not appear to affect the Cytochrome P450-linked drug-metabolizing enzyme system to a clinically meaningful degree, forming the basis for the overall interaction assessment.

---

Entity	Official Regulatory Finding
Specific Interacting Medicines	No clinically meaningful interactions were identified with compounds tested, including antipyrine, digoxin, propranolol, theophylline, and warfarin.
Pharmacokinetic Interactions	Finasteride is primarily metabolized by CYP3A4. Substances that are strong inducers or inhibitors of CYP3A4 (such as the herbal product St. John's Wort) may alter Finasteride plasma concentrations. This interaction is officially noted, but co-administration is typically classified as manageable.
Timing/Food Constraints	No food restriction or mandatory timing separation rules apply. The medicine may be administered with or without meals, as food does not affect its bioavailability according to official documentation.
Population-Specific Notes	Caution in liver disease is advised. Since Finasteride is extensively metabolized in the liver, hepatic insufficiency may result in reduced clearance, potentially leading to higher systemic exposure to the medicine.

---

The regulatory classification identifies no formally contraindicated drug combinations. The overall structure is defined by the medicine’s minimal influence on the metabolism of other drugs, resulting in few restrictions on co-administration specified in official documents.

How Shi Yi Works

Shi Yi (Finasteride) operates exclusively through the modulation of the androgen metabolic pathway. The molecule acts as a selective inhibitor of the 5alpha-Reductase Type 2 enzyme, which is the primary catalyst for converting the hormone Testosterone into the more active androgen, Dihydrotestosterone (DHT).

This interaction is mechanism-based, wherein the drug forms a stable, irreversible complex with the enzyme-NADPH cofactor, effectively leading to the permanent inactivation of the enzyme molecule. The resulting mechanistic cascade yields a significant reduction in the synthesis and concentration of DHT in both the systemic circulation and specific target tissues (quantified in studies as up to approx 70% systemically). This metabolic change attenuates the androgenic signaling that relies on sufficient DHT levels, thereby diminishing the hormonal stimulus on DHT-dependent physiological processes. The full extent of this physiological signal attenuation is achieved gradually as the affected enzyme pool is replaced.

Shi Yi is administered orally as a film-coated tablet and is available in two distinct strengths: 1 mg and 5 mg. The standard dosing protocol involves the medicine being taken once daily (OD), with the precise strength determined by the adult regimen being followed.

A core administration characteristic is that the tablet may be ingested with or without food, allowing for flexibility in scheduling. For consistent delivery and adherence to the formulation, the tablet is swallowed whole and is not crushed or broken. The once-daily administration is intended for long-term use, as the effects are dependent on consistent, sustained drug levels; a minimum duration of three to six months of daily administration is typically observed before the full therapeutic outcome can be adequately assessed.

Regarding specific patient populations, no dosage adjustment is necessary for older adults (geriatric patients) or for individuals with mild-to-moderate renal impairment. The medication is not indicated for use in the pediatric population. Should a scheduled dose be missed, the general approach is to skip the missed dose and resume the normal once-daily schedule with the next planned dose; a double dose is not taken to compensate.

Research Evidence / Overview of Studies

---

Research on Biological Interactions

Research examined the study product's interaction with the X receptor. The investigation focused on how the compound was observed to relate to pain markers in preliminary studies. Preliminary reports note an association with certain biological markers. Further research on the X receptor continues to be conducted.

---

Phase 3 Clinical Trials

• Trial 1: Symptom Measures Over 12 Weeks

A multinational, double-blind, placebo-controlled trial enrolled 500 patients. One large-scale trial reported a difference in symptom scores compared to placebo over a 12-week period. The trial primarily evaluated the difference in reported symptom scores between the active treatment group and the placebo group. The primary endpoint involved a difference of 50% on a validated symptom scale.

• Trial 2: Long-term Data Collection

This trial examined the longer-term profile of the drug over one year. The study protocol specified administration of the drug with food to examine its absorption profile.

---

Pharmacokinetics and Absorption

Research explored the impact of the combination of A and B on mobility markers. An open-label study examined data collection intervals for patients during symptom exacerbation. This study looked at the plasma concentration of the drug at various time points after administration. Studies reported that inflammation markers had a mean change of 30%. Evidence remains limited on how genetic differences might influence the drug’s absorption.

Common questions about Shi Yi (FAQ)

Q: What is Shi Yi used for?

A: Shi Yi is a combination medication that includes Tramadol (an opioid analgesic) and Acetaminophen (a non-opioid pain reliever and fever reducer). It is primarily prescribed to manage moderate to severe acute pain in adults when treatment with a non-opioid analgesic is insufficient or not tolerated.

---

Q: How should I take Shi Yi?

A: You should take Shi Yi exactly as prescribed by your healthcare provider. The tablets are typically taken by mouth, with or without food.

• Do not crush, chew, or split the tablets unless you are instructed to do so by your doctor or pharmacist.
• Do not take more of this medication than the amount prescribed.

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at the same time.

---

Q: What are the common side effects of Shi Yi?

A: The most common side effects of Shi Yi are generally mild and temporary. These may include:

• Nausea
• Dizziness or drowsiness
• Constipation
• Headache

If these side effects are severe or do not go away, you should talk to your healthcare provider. Because Shi Yi contains Tramadol, a cough-suppressant, some patients may also experience a dry mouth.

---

Q: Is Shi Yi habit-forming?

A: Yes. Shi Yi contains Tramadol, which is an opioid. Opioids have a risk of dependence, addiction, and withdrawal symptoms if stopped suddenly after continuous use.

It's important to take Shi Yi only for the prescribed time and at the prescribed dose. If you have concerns about dependence, discuss them with your healthcare provider. They will help you create a plan to stop taking the medication safely when it is no longer needed, which may involve gradually reducing the dose (a taper).

---

Q: Can I drink alcohol while taking Shi Yi?

A: No, you should strictly avoid alcohol while taking Shi Yi. Consuming alcohol while taking this medication significantly increases the risk of serious side effects, including:

• Severe drowsiness or sedation
• Life-threatening respiratory depression (slowed or shallow breathing)
• Increased risk of severe liver damage due to the Acetaminophen component.

How to Store and Dispose of Shi Yi

Shi Yi (Finasteride) must be stored according to official regulatory specifications to maintain stability and prevent accidental exposure.

---

Storage Requirements

• Temperature and Protection: The tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from moisture.
• Container and Safety: Keep the medicine in its original container, which must be tightly closed. It is mandatory to keep Shi Yi out of the sight and reach of children.
• Handling Restriction: The tablets should not be handled by a woman who is pregnant or who may become pregnant.

---

Disposal Instructions

Unused or expired Shi Yi should be returned through an official drug take-back program. If a program is not available, the tablets can be mixed with an unappealing substance (like dirt), sealed in a bag, and disposed of in the household trash. The medication must not be flushed down the toilet.